| Identification | Back Directory | [Name]
Benzoic acid, 2-[[(3'-butoxy-3-chloro-5-fluoro[1,1'-biphenyl]-4-yl)amino]carbonyl]- | [CAS]
1346705-53-0 | [Synonyms]
DHODH-IN-23
Benzoic acid, 2-[[(3'-butoxy-3-chloro-5-fluoro[1,1'-biphenyl]-4-yl)amino]carbonyl]- | [Molecular Formula]
C24H21ClFNO4 | [MOL File]
1346705-53-0.mol | [Molecular Weight]
441.88 |
| Chemical Properties | Back Directory | [Boiling point ]
526.9±50.0 °C(Predicted) | [density ]
1.315±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.33±0.36(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer[1]. | [in vivo]
DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) shows antitumor activity in MV411 mouse xenograft model[1]. | Animal Model: | MV411 mouse xenograft model[1] | | Dosage: | 30 mg/kg | | Administration: | Oral administration, twice daily for 21 days | | Result: | Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively. |
| [References]
[1] Srikant Viswanadha, et al. Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia. Patent WO2021079273A1. |
|
|